DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
13F Reported Value
ⓘ$9.6B
Holdings
82
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) disclosed 82 positions worth $9.6B in its Form 13F-HR for Q2 2026, led by $NUVL (Nuvalent, Inc.) at 22.2% of the equity portfolio. During the quarter the fund opened 10 new positions and exited 12 — including a new stake in $MLYS and a full exit from $CPRX. The portfolio is most concentrated in Healthcare (89.0% of disclosed assets). All figures are sourced directly from DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)’s Form 13F-HR filing with the SEC under CIK 1009258.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$2.1B17,248,450 sh BROOKDALE SR LIVING INC - NOTE 3.500%10/1
—Quality
$585.7M306,885,000 sh- —
Quality
$448.0M2,392,000 sh - $322.5M963,351 sh
- 45.4
Quality
$320.9M20,206,170 sh - 58.2
Quality
$314.6M4,901,000 sh - —
Quality
$251.7M200,000,000 sh - 71.3
Quality
$247.6M457,000 sh ARROWHEAD PHARMACEUTICALS IN - NOTE 1/1
—Quality
$240.5M200,000,000 sh- 47.8
Quality
$235.0M8,137,638 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Nuvalent, Inc.$NUVL | — | $2.1B | 17,248,450 |
| BROOKDALE SR LIVING INC - NOTE 3.500%10/1 | — | $585.7M | 306,885,000 |
 Revolution Medicines, Inc.$RVMD | — | $448.0M | 2,392,000 |
 Praxis Precision Medicines, Inc.$PRAX | — | $322.5M | 963,351 |
 Viatris Inc$VTRS | 45.4 | $320.9M | 20,206,170 |
 CENTENE CORP$CNC | 58.2 | $314.6M | 4,901,000 |
| Revolution Medicines, Inc.$RVMD | — | $251.7M | 200,000,000 |
 UNITED THERAPEUTICS Corp$UTHR | 71.3 | $247.6M | 457,000 |
| ARROWHEAD PHARMACEUTICALS IN - NOTE 1/1 | — | $240.5M | 200,000,000 |
 Legend Biotech Corp$LEGN | 47.8 | $235.0M | 8,137,638 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 82 positions.
Showing top 10 of 82 holdings.
Sector Allocation
Healthcare
$8.5B
Other
$906.6M
Technology
$144.0M
Full Holdings — DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (Q2 2026)
All 82 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $NUVL | Nuvalent, Inc. | $2.1B | 22.2% | +0% | — |
| 2 | — | BROOKDALE SR LIVING INC - NOTE 3.500%10/1 | $585.7M | 6.1% | +0% | — |
| 3 | $RVMD | Revolution Medicines, Inc. | $448.0M | 4.7% | +4% | — |
| 4 | $PRAX | Praxis Precision Medicines, Inc. | $322.5M | 3.4% | +0% | — |
| 5 | $VTRS | Viatris Inc | $320.9M | 3.4% | +0% | 45.4 |
| 6 | $CNC | CENTENE CORP | $314.6M | 3.3% | -17% | 58.2 |
| 7 | $RVMD | Revolution Medicines, Inc. | $251.7M | 2.6% | NEW | — |
| 8 | $UTHR | UNITED THERAPEUTICS Corp | $247.6M | 2.6% | +0% | 71.3 |
| 9 | — | ARROWHEAD PHARMACEUTICALS IN - NOTE 1/1 | $240.5M | 2.5% | +0% | — |
| 10 | $LEGN | Legend Biotech Corp | $235.0M | 2.5% | +6% | 47.8 |
| 11 |  $COGT | Cogent Biosciences, Inc. | $193.7M | 2.0% | -45% | — |
| 12 |  $GMAB | GENMAB A/S | $188.6M | 2.0% | +179% | 77.9 |
| 13 |  $BKD | Brookdale Senior Living Inc. | $187.2M | 1.9% | +0% | 44.1 |
| 14 |  $VERA | Vera Therapeutics, Inc. | $168.1M | 1.8% | +5% | — |
| 15 |  $IONS | IONIS PHARMACEUTICALS INC | $157.0M | 1.6% | +0% | 23.4 |
| 16 |  $CELC | Celcuity Inc. | $151.8M | 1.6% | -15% | — |
| 17 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $151.0M | 1.6% | +0% | 53.2 |
| 18 |  $NAMS | NewAmsterdam Pharma Co N.V. | $144.5M | 1.5% | +0% | — |
| 19 |  $ACHC | Acadia Healthcare Company, Inc. | $133.5M | 1.4% | +0% | 36.7 |
| 20 |  $TNGX | Tango Therapeutics, Inc. | $131.0M | 1.4% | +1% | 17.6 |
| 21 |  $AHCO | AdaptHealth Corp. | $119.6M | 1.3% | +0% | 42.3 |
| 22 |  $PHVS | Pharvaris N.V. | $116.7M | 1.2% | +8% | — |
| 23 | $CELC | Celcuity Inc. | $113.8M | 1.2% | NEW | — |
| 24 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $113.2M | 1.2% | -12% | 38.7 |
| 25 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $109.7M | 1.1% | +10% | 22.6 |
| 26 |  $LRMR | Larimar Therapeutics, Inc. | $108.6M | 1.1% | +0% | — |
| 27 |  $MLYS | Mineralys Therapeutics, Inc. | $106.8M | 1.1% | NEW | — |
| 28 |  $ALHC | Alignment Healthcare, Inc. | $103.8M | 1.1% | +0% | 64.2 |
| 29 |  $IDYA | IDEAYA Biosciences, Inc. | $101.2M | 1.1% | +77% | 36.1 |
| 30 |  $XENE | Xenon Pharmaceuticals Inc. | $97.5M | 1.0% | +0% | 24 |
| 31 | $IONS | IONIS PHARMACEUTICALS INC | $93.1M | 1.0% | +0% | 23.4 |
| 32 |  $SVRA | Savara Inc | $83.6M | 0.9% | +0% | — |
| 33 |  $LNTH | Lantheus Holdings, Inc. | $83.5M | 0.9% | -9% | 61.1 |
| 34 |  $SNDX | Syndax Pharmaceuticals Inc | $82.6M | 0.9% | +0% | 33.8 |
| 35 | — | ZENAS BIOPHARMA INC - NOTE 2.500% 4/0 | $80.3M | 0.8% | +3% | — |
| 36 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $76.3M | 0.8% | +57% | 58.2 |
| 37 |  $PFE | PFIZER INC | $73.2M | 0.8% | +0% | 62 |
| 38 |  $INDV | Indivior Pharmaceuticals, Inc. | $67.7M | 0.7% | -47% | 58.5 |
| 39 |  $BIO | BIO-RAD LABORATORIES, INC. | $66.4M | 0.7% | +0% | 48.9 |
| 40 |  $SPRY | ARS Pharmaceuticals, Inc. | $60.1M | 0.6% | +0% | 20.3 |
| 41 |  $STOK | Stoke Therapeutics, Inc. | $59.7M | 0.6% | +0% | 24.9 |
| 42 |  $GPCR | Structure Therapeutics Inc. | $58.3M | 0.6% | +41% | — |
| 43 |  $NVST | Envista Holdings Corp | $58.2M | 0.6% | +0% | 54.9 |
| 44 |  $INSP | Inspire Medical Systems, Inc. | $57.9M | 0.6% | -52% | 63.7 |
| 45 |  $CDNA | CareDx, Inc. | $56.9M | 0.6% | -9% | 67.5 |
| 46 |  $BSX | BOSTON SCIENTIFIC CORP | $56.1M | 0.6% | NEW | 77.5 |
| 47 |  $BLTE | BELITE BIO, INC | $55.0M | 0.6% | +17% | — |
| 48 |  $PBLS | Parabilis Medicines, Inc. | $51.5M | 0.5% | NEW | — |
| 49 |  $CERT | Certara, Inc. | $49.2M | 0.5% | -4% | 39.1 |
| 50 |  $IRON | Disc Medicine, Inc. | $48.1M | 0.5% | +0% | — |
| 51 |  $LIVN | LivaNova PLC | $46.5M | 0.5% | +0% | — |
| 52 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $37.2M | 0.4% | +0% | — |
| 53 |  $TYRA | Tyra Biosciences, Inc. | $32.5M | 0.3% | +85% | — |
| 54 |  $MNPR | Monopar Therapeutics | $30.0M | 0.3% | +0% | — |
| 55 |  $SION | Sionna Therapeutics, Inc. | $30.0M | 0.3% | -30% | — |
| 56 |  $IMCR | Immunocore Holdings plc | $27.1M | 0.3% | +0% | — |
| 57 |  $AVLN | Avalyn Pharma Inc. | $24.1M | 0.3% | NEW | — |
| 58 |  $FHTX | Foghorn Therapeutics Inc. | $21.4M | 0.2% | +0% | 16.1 |
| 59 |  $BBNX | Beta Bionics, Inc. | $20.7M | 0.2% | +0% | 29.8 |
| 60 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $20.5M | 0.2% | +0% | 71.4 |
| 61 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $19.9M | 0.2% | +0% | — |
| 62 |  $ODTX | Odyssey Therapeutics, Inc. | $19.6M | 0.2% | NEW | — |
| 63 |  $STLN | Starling Oncology, Inc. | $18.2M | 0.2% | +0% | 45.2 |
| 64 |  $KYTX | Kyverna Therapeutics, Inc. | $17.8M | 0.2% | +0% | — |
| 65 |  $ALMR | Alamar Biosciences, Inc. | $16.3M | 0.2% | NEW | — |
| 66 |  $CHE | CHEMED CORP | $14.0M | 0.1% | NEW | 62.9 |
| 67 |  $SGP | SpyGlass Pharma, Inc. | $12.2M | 0.1% | +0% | — |
| 68 |  $NEO | NEOGENOMICS INC | $12.2M | 0.1% | -82% | 34.3 |
| 69 |  $ADAG | Adagene Inc. | $11.2M | 0.1% | NEW | — |
| 70 |  $COAG | Hemab Therapeutics Holdings, Inc. | $10.1M | 0.1% | NEW | — |
| 71 |  $MOBI | Mobia Medical, Inc. | $9.0M | 0.1% | NEW | — |
| 72 |  $EMBC | Embecta Corp. | $8.3M | 0.1% | +0% | 50.2 |
| 73 |  $VCYT | VERACYTE, INC. | $5.9M | 0.1% | -86% | 68.6 |
| 74 |  $ANNX | Annexon, Inc. | $3.3M | 0.0% | +0% | — |
| 75 |  $ALEC | Alector, Inc. | $2.1M | 0.0% | +0% | 10.9 |
| 76 | $NAMS | NewAmsterdam Pharma Co N.V. | $2.0M | 0.0% | +0% | — |
| 77 |  $EW | Edwards Lifesciences Corp | $1.2M | 0.0% | +0% | 69.4 |
| 78 |  $MIRM | Mirum Pharmaceuticals, Inc. | $705,581 | 0.0% | -100% | 35 |
| 79 |  $HUM | HUMANA INC | $364,251 | 0.0% | +0% | 58.9 |
| 80 | $STLN | Starling Oncology, Inc. | $51,000 | 0.0% | +0% | 45.2 |
| 81 |  $PMVP | PMV Pharmaceuticals, Inc. | $11,779 | 0.0% | +0% | — |
| 82 |  $SRZN | Surrozen, Inc./DE | $2,750 | 0.0% | +0% | — |
New Positions (10)
$MLYS Mineralys Therapeutics, Inc.$106.8M$BSX BOSTON SCIENTIFIC CORP$56.1M$PBLS Parabilis Medicines, Inc.$51.5M$AVLN Avalyn Pharma Inc.$24.1M$ODTX Odyssey Therapeutics, Inc.$19.6M$ALMR Alamar Biosciences, Inc.$16.3M$CHE CHEMED CORP$14.0M$ADAG Adagene Inc.$11.2M$COAG Hemab Therapeutics Holdings, Inc.$10.1M$MOBI Mobia Medical, Inc.$9.0MExited Positions (12)
$CPRX CATALYST PHARMACEUTICALS, INC.
$NBIX NEUROCRINE BIOSCIENCES INC
$DAWN Day One Biopharmaceuticals, Inc.
$EHAB Enhabit, Inc.
$KYMR Kymera Therapeutics, Inc.
$CMPX Compass Therapeutics, Inc.
$TSHA Taysha Gene Therapies, Inc.
$CGEM Cullinan Therapeutics, Inc.
$PHGE BiomX Inc.
$MANE Veradermics, Inc
$QSI Quantum-Si Inc
$MYGN MYRIAD GENETICS INCBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) including:
Track DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
13F Pro is an AI hedge fund tracker and stock research platform. For DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (SEC CIK: 1009258), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.